GlobeImmune Company Profile (NASDAQ:GBIM)

About GlobeImmune (NASDAQ:GBIM)

GlobeImmune logoGlobeImmune, Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company's segment is the business of developing and commercializing various biopharmaceutical products. The Company's infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Company's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GBIM
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $1.9 million
  • Outstanding Shares: 5,751,000
Average Prices:
  • 50 Day Moving Avg: $0.28
  • 200 Day Moving Avg: $0.37
  • 52 Week Range: $0.11 - $3.38
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $6.21 million
  • Price / Sales: 0.31
  • Book Value: $0.37 per share
  • Price / Book: 0.89
Profitability:
  • EBIDTA: ($1,940,000.00)
Misc:
  • Average Volume: 41,258 shs.
  • Beta: 2.8
  • Short Ratio: 0.1
 

Frequently Asked Questions for GlobeImmune (NASDAQ:GBIM)

What is GlobeImmune's stock symbol?

GlobeImmune trades on the NASDAQ under the ticker symbol "GBIM."

How were GlobeImmune's earnings last quarter?

GlobeImmune Inc (NASDAQ:GBIM) posted its quarterly earnings data on Thursday, May, 12th. The company reported ($0.15) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.12. The firm earned $0.94 million during the quarter. View GlobeImmune's Earnings History.

Who are some of GlobeImmune's key competitors?

How do I buy GlobeImmune stock?

Shares of GlobeImmune can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of GlobeImmune stock cost?

One share of GlobeImmune stock can currently be purchased for approximately $0.33.

Analyst Ratings

Consensus Ratings for GlobeImmune (NASDAQ:GBIM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for GlobeImmune (NASDAQ:GBIM)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for GlobeImmune (NASDAQ:GBIM)
Earnings by Quarter for GlobeImmune (NASDAQ:GBIM)
Earnings History by Quarter for GlobeImmune (NASDAQ:GBIM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2016Q1($0.27)($0.15)$0.94 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GlobeImmune (NASDAQ:GBIM)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for GlobeImmune (NASDAQ:GBIM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for GlobeImmune (NASDAQ:GBIM)
Insider Trades by Quarter for GlobeImmune (NASDAQ:GBIM)
Insider Trades by Quarter for GlobeImmune (NASDAQ:GBIM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/18/2016Augustine LawlorDirectorSell11,000$1.55$17,050.00View SEC Filing  
3/17/2016Daniel J MitchellDirectorSell21,600$1.66$35,856.00View SEC Filing  
3/15/2016Daniel J MitchellDirectorSell130,269$2.26$294,407.94View SEC Filing  
3/11/2016Augustine LawlorDirectorSell16,500$1.60$26,400.00View SEC Filing  
3/10/2016Daniel J MitchellDirectorSell16,400$1.17$19,188.00View SEC Filing  
3/8/2016Augustine LawlorDirectorSell15,010$1.05$15,760.50View SEC Filing  
3/7/2016Daniel J MitchellDirectorSell11,920$1.05$12,516.00View SEC Filing  
3/3/2016Augustine LawlorDirectorSell15,990$1.11$17,748.90View SEC Filing  
3/2/2016Daniel J MitchellDirectorSell17,422$1.02$17,770.44View SEC Filing  
3/1/2016Daniel J MitchellDirectorSell8,799$0.96$8,447.04View SEC Filing  
2/29/2016Augustine LawlorDirectorSell15,000$0.98$14,700.00View SEC Filing  
2/26/2016Daniel J MitchellDirectorSell12,501$1.03$12,876.03View SEC Filing  
2/24/2016Augustine LawlorDirectorSell15,000$1.33$19,950.00View SEC Filing  
2/23/2016Daniel J MitchellDirectorSell22,858$1.42$32,458.36View SEC Filing  
2/22/2016Augustine LawlorDirectorSell5,000$1.43$7,150.00View SEC Filing  
2/19/2016Ventures Vii Lp HealthcareInsiderSell15,000$1.44$21,600.00View SEC Filing  
2/18/2016Daniel J MitchellDirectorSell21,897$1.45$31,750.65View SEC Filing  
2/16/2016Ventures Vii Lp HealthcareMajor ShareholderSell15,000$1.61$24,150.00View SEC Filing  
2/12/2016Daniel J MitchellDirectorSell3,645$1.75$6,378.75View SEC Filing  
2/9/2016Daniel J MitchellDirectorSell7,300$2.05$14,965.00View SEC Filing  
7/8/2014Celgene International IncMajor ShareholderBuy200,000$10.00$2,000,000.00View SEC Filing  
7/8/2014S. Edward TorresDirectorBuy85,000$10.00$850,000.00View SEC Filing  
7/8/2014Timothy C Rodell JrCEOBuy5,000$10.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for GlobeImmune (NASDAQ:GBIM)
Latest Headlines for GlobeImmune (NASDAQ:GBIM)
Source:
DateHeadline
americanbankingnews.com logoGlobeImmune (GBIM) Given Daily News Impact Score of 0.12
www.americanbankingnews.com - April 25 at 8:36 PM
us.rd.yahoo.com logo4:06 pm Globelmmune enters into a definitive purchase agreement for the sale of 12,835,490 shares of its common stock to NantCell a member of the NantWorks ecosystem of companies
us.rd.yahoo.com - March 23 at 10:55 PM
rttnews.com logoTENX Awaits Data In Jan, GBIM Hit Hard, FDA Says No To SPPI
www.rttnews.com - November 21 at 10:15 AM
investopedia.com logoGilead CEO Resigns, Dumps GlobeImmune Pact (GILD)
www.investopedia.com - November 18 at 4:41 PM
finance.yahoo.com logo3:55 am Globelmmune provides corporate update; CEO resigns, Gilead (GILD) terminates collaboration and license agreement
finance.yahoo.com - November 18 at 8:01 AM
nasdaq.com logoMid-Day Market Update: U.S. Stocks Turn Positive; Nortek Shares Surge Following Acquisition News
www.nasdaq.com - July 6 at 5:18 PM
streetinsider.com logoAfter-Hours Stock Movers 07/05: (EGLE) (MDVN) (BIIB) Higher; (GBIM) (VTR) (TSLA) Lower (more...)
www.streetinsider.com - July 6 at 5:18 PM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T
biz.yahoo.com - July 5 at 4:44 PM
finance.yahoo.com logoGlobeImmune Announces Delisting and Deregistration of Common Stock
finance.yahoo.com - July 5 at 4:30 PM
bizjournals.com logoIs this Colorado biotech a takeover target?
www.bizjournals.com - June 20 at 11:22 AM
baystreet.ca logoThese Four Companies Are a Must for Your Watchlist, in June
www.baystreet.ca - June 17 at 5:02 PM
investopedia.com logoMarkets Rally Belatedly To ECB Bazooka (GBIM)
www.investopedia.com - March 11 at 11:47 AM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - February 23 at 4:12 PM
finance.yahoo.com logoGLOBEIMMUNE INC Financials
finance.yahoo.com - December 8 at 1:18 PM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - November 13 at 9:12 AM
finance.yahoo.com logoGlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights
finance.yahoo.com - November 13 at 6:30 AM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 13 at 6:15 AM
finance.yahoo.com logoGlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights
finance.yahoo.com - August 14 at 6:30 AM
finance.yahoo.com logoGlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options
finance.yahoo.com - August 13 at 6:30 AM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - August 4 at 4:29 PM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - July 17 at 4:31 PM
biz.yahoo.com logoGLOBEIMMUNE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - July 13 at 4:12 PM

Social

Chart

GlobeImmune (GBIM) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff